U 89678

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H462845

CAS#: 157744-31-5

Description: U 89678 is a tirilazad mesylate metabolite that has protective effects against blood-brain barrier damage after subarachnoid hemorrhage and lipid peroxidative neuronal injury.


Chemical Structure

img
U 89678
CAS# 157744-31-5

Theoretical Analysis

Hodoodo Cat#: H462845
Name: U 89678
CAS#: 157744-31-5
Chemical Formula: C38H54N6O2
Exact Mass: 626.43
Molecular Weight: 626.890
Elemental Analysis: C, 72.81; H, 8.68; N, 13.41; O, 5.10

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: U-89678; U89678;

IUPAC/Chemical Name: (5R,8S,10R,13S,14S,16R,17S)-17-(2-(2-(2,6-di(pyrrolidin-1-yl)pyrimidin-4-yl)piperazin-1-yl)acetyl)-10,13,16-trimethyl-4,5,6,7,8,10,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one

InChi Key: XJKDZKQCLJIYNZ-UVBXRMJNSA-N

InChi Code: InChI=1S/C38H54N6O2/c1-25-20-30-28-9-8-26-21-27(45)10-12-37(26,2)29(28)11-13-38(30,3)35(25)33(46)24-44-19-14-39-23-32(44)31-22-34(42-15-4-5-16-42)41-36(40-31)43-17-6-7-18-43/h10-12,22,25-26,28,30,32,35,39H,4-9,13-21,23-24H2,1-3H3/t25-,26-,28-,30+,32?,35-,37+,38+/m1/s1

SMILES Code: C[C@@H]1C[C@H]2[C@@H]3CC[C@@H]4CC(C=C[C@@]4(C3=CC[C@@]2([C@H]1C(CN5CCNCC5c6nc(N7CCCC7)nc(N8CCCC8)c6)=O)C)C)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 626.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Smith SL, Scherch HM, Hall ED. Protective effects of tirilazad mesylate and metabolite U-89678 against blood-brain barrier damage after subarachnoid hemorrhage and lipid peroxidative neuronal injury. J Neurosurg. 1996 Feb;84(2):229-33. doi: 10.3171/jns.1996.84.2.0229. PMID: 8592225.

2: Fleishaker JC, Peters GR. Pharmacokinetics of tirilazad and U-89678 in ischemic stroke patients receiving a loading regimen and maintenance regimen of 10 mg/kg/day of tirilazad. J Clin Pharmacol. 1996 Sep;36(9):809-13. doi: 10.1002/j.1552-4604.1996.tb04254.x. PMID: 8889901.

3: Fleishaker JC, Straw RN, Cross CJ. Pharmacokinetics of tirilazad and U-89678, an active, reduced metabolite, following acute head trauma in adults. J Pharm Sci. 1997 Apr;86(4):434-7. doi: 10.1021/js960410e. PMID: 9109044.

4: Wienkers LC, Steenwyk RC, Hauer MJ, Fleishaker JC, Pearson PG. Biotransformation of tirilazad in human: 3. tirilazad A-ring reduction by human liver microsomal 5alpha-reductase type 1 and type 2. J Pharmacol Exp Ther. 1998 Nov;287(2):583-90. PMID: 9808684.

5: Fleishaker JC, Hulst-Pearson LK, Peters GR. Effect of Gender and Menopausal Status on the Pharmacokinetics of Tirilazad Mesylate in Healthy Subjects. Am J Ther. 1995 Aug;2(8):553-560. doi: 10.1097/00045391-199508000-00007. PMID: 11854826.

6: Fleishaker JC, Pearson LK, Peters GR. Gender does not affect the degree of induction of tirilazad clearance by phenobarbital. Eur J Clin Pharmacol. 1996;50(1-2):139-45. doi: 10.1007/s002280050082. PMID: 8739825.

7: Fleishaker JC, Hulst LK, Peters GR. The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers. Clin Pharmacol Ther. 1994 Oct;56(4):389-97. doi: 10.1038/clpt.1994.153. PMID: 7955800.

8: Fleishaker JC, Hulst LK, Peters GR. Multiple-dose tolerability and pharmacokinetics of tirilazad mesylate at doses of up to 10 mg/kg/day administered over 5-10 days in healthy volunteers. Int J Clin Pharmacol Ther. 1994 May;32(5):223-30. PMID: 7921515.

9: Fleishaker JC, Peters GR. Pharmacokinetics of tirilazad in healthy male subjects at doses above 6 mg/kg/day. Int J Clin Pharmacol Ther. 1997 Jan;35(1):28-32. PMID: 9021439.

10: Fleishaker JC, Pearson LK, Peters GR. Induction of tirilazad clearance by phenytoin. Biopharm Drug Dispos. 1998 Mar;19(2):91-6. doi: 10.1002/(sici)1099-081x(199803)19:2<91::aid-bdd78>3.0.co;2-t. PMID: 9533108.

11: Fleishaker JC, Pearson PG, Wienkers LC, Pearson LK, Moore TA, Peters GR. Biotransformation of tirilazad in human: 4. effect of finasteride on tirilazad clearance and reduced metabolite formation. J Pharmacol Exp Ther. 1998 Nov;287(2):591-7. PMID: 9808685.

12: Fleishaker JC, Pearson PG, Wienkers LC, Pearson LK, Peters GR. Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. J Pharmacol Exp Ther. 1996 May;277(2):991-8. PMID: 8627582.

13: Bombardt PA, Brewer JE, Johnson MG. Protein binding of tirilazad (U-74006) in human, Sprague-Dawley rat, beagle dog and cynomolgus monkey serum. J Pharmacol Exp Ther. 1994 Apr;269(1):145-50. PMID: 8169818.

14: Pearson LK, Fleishaker JC, Peters GR. Comparison of the pharmacokinetics of tirilazad mesylate in healthy volunteers and stable subjects with mild liver cirrhosis. Eur J Clin Pharmacol. 1996;50(4):299-304. doi: 10.1007/s002280050112. PMID: 8803523.